Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence
Age-related physiological changes, such as impaired organ function (i.e., renal, cardiac), frailty, reduced bone marrow reserves and altered pharmacokinetics, complicate treatment decisions and compromise survival in older patients with cancer. Immune checkpoint inhibitors (ICIs) have transformed th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.22.165 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127641639649280 |
|---|---|
| author | Marcus Vetter Vérène Dougoud-Chauvin Laure Poudens Gaudout Anita Margulies Jan Gärtner Till Wallrabenstein Nina Rosa Neuendorff Claudia Bollinger Michael Gagesch Mathias Schlögl |
| author_facet | Marcus Vetter Vérène Dougoud-Chauvin Laure Poudens Gaudout Anita Margulies Jan Gärtner Till Wallrabenstein Nina Rosa Neuendorff Claudia Bollinger Michael Gagesch Mathias Schlögl |
| author_sort | Marcus Vetter |
| collection | DOAJ |
| description | Age-related physiological changes, such as impaired organ function (i.e., renal, cardiac), frailty, reduced bone marrow reserves and altered pharmacokinetics, complicate treatment decisions and compromise survival in older patients with cancer. Immune checkpoint inhibitors (ICIs) have transformed the landscape of cancer treatment, offering significant survival benefits across various malignancies, including older populations. However, aging can influence the effectiveness of ICIs and increase patient susceptibility to immune-related toxicities, resulting in poorer outcomes. The impact of age and frailty on the effectiveness and safety of ICI therapy remains poorly understood. This review examines recent data on the use of ICIs in older, frail patients with cancer. Existing evidence highlights the need for personalized approaches when using ICIs and calls for further research on treatment adaptations that could maximize benefits while minimizing risks in this vulnerable population.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Ursula Hasler-Strub, Cantonal Hospital Graubünden, Chur, Switzerland
Dr Andreas Hochstrasser, Hospital Simmental-Thun-Saanenland (STS), Thun, Switzerland
Received on November 11, 2024; accepted after peer review on December 28, 2024; published online on December 30, 2024. |
| format | Article |
| id | doaj-art-b47b7811cfd6496b8fc5dd88309da40e |
| institution | OA Journals |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-b47b7811cfd6496b8fc5dd88309da40e2025-08-20T02:33:38ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062024-12-0122410.36000/HBT.OH.2024.22.165Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current EvidenceMarcus VetterVérène Dougoud-ChauvinLaure Poudens GaudoutAnita MarguliesJan GärtnerTill WallrabensteinNina Rosa NeuendorffClaudia BollingerMichael GageschMathias SchlöglAge-related physiological changes, such as impaired organ function (i.e., renal, cardiac), frailty, reduced bone marrow reserves and altered pharmacokinetics, complicate treatment decisions and compromise survival in older patients with cancer. Immune checkpoint inhibitors (ICIs) have transformed the landscape of cancer treatment, offering significant survival benefits across various malignancies, including older populations. However, aging can influence the effectiveness of ICIs and increase patient susceptibility to immune-related toxicities, resulting in poorer outcomes. The impact of age and frailty on the effectiveness and safety of ICI therapy remains poorly understood. This review examines recent data on the use of ICIs in older, frail patients with cancer. Existing evidence highlights the need for personalized approaches when using ICIs and calls for further research on treatment adaptations that could maximize benefits while minimizing risks in this vulnerable population. PEER REVIEWED ARTICLE **Peer reviewers:** Dr Ursula Hasler-Strub, Cantonal Hospital Graubünden, Chur, Switzerland Dr Andreas Hochstrasser, Hospital Simmental-Thun-Saanenland (STS), Thun, Switzerland Received on November 11, 2024; accepted after peer review on December 28, 2024; published online on December 30, 2024.https://doi.org/10.36000/HBT.OH.2024.22.165 |
| spellingShingle | Marcus Vetter Vérène Dougoud-Chauvin Laure Poudens Gaudout Anita Margulies Jan Gärtner Till Wallrabenstein Nina Rosa Neuendorff Claudia Bollinger Michael Gagesch Mathias Schlögl Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence healthbook TIMES. Oncology Hematology |
| title | Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence |
| title_full | Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence |
| title_fullStr | Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence |
| title_full_unstemmed | Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence |
| title_short | Immune Checkpoint Inhibitors in Frail Older Patients: A Review of Current Evidence |
| title_sort | immune checkpoint inhibitors in frail older patients a review of current evidence |
| url | https://doi.org/10.36000/HBT.OH.2024.22.165 |
| work_keys_str_mv | AT marcusvetter immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT verenedougoudchauvin immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT laurepoudensgaudout immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT anitamargulies immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT jangartner immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT tillwallrabenstein immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT ninarosaneuendorff immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT claudiabollinger immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT michaelgagesch immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence AT mathiasschlogl immunecheckpointinhibitorsinfrailolderpatientsareviewofcurrentevidence |